Dashboard
Manage Tickers

RCKTROCKET PHARMACEUTICALS, INC.

Nasdaq rocketpharma.com


$ 21.55 $ 0.10 (0.47 %)    

Friday, 28-Jun-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 21.53
$ 18.80
$ 0.00 x 0
$ 0.00 x 0
$ 18.67 - $ 21.59
$ 14.89 - $ 32.53
4,001,952
na
2.01B
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-06-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-08-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-11-2018 03-31-2018 10-Q
26 03-07-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-10-2016 06-30-2016 10-Q
33 05-11-2016 03-31-2016 10-Q
34 03-23-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-Q
37 05-14-2015 03-31-2015 10-Q
38 03-31-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chardan-capital-maintains-buy-on-rocket-pharmaceuticals-maintains-62-price-target
Chardan Capital Maintains Buy on Rocket Ph...
06/28/2024 19:05:55

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price ta...

needham-maintains-buy-on-rocket-pharmaceuticals-lowers-price-target-to-52
Needham Maintains Buy on Rocket Pharmaceut...
06/28/2024 14:51:01

Needham analyst Gil Blum maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $53 to $52.

fda-rejects-rocket-pharmaceuticals-gene-therapy-for-rare-immune-disorder-asks-for-more-data-stock-slides
FDA Rejects Rocket Pharmaceuticals' Gene T...
06/28/2024 13:52:06

Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leuk...

nike-accolade-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Nike, Accolade And Other Big Stocks Moving...
06/28/2024 13:08:43

trading-halt-halt-status-updated-at-75500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:55:...
06/28/2024 11:55:05

the-fda-issued-complete-response-letter-to-rocket-pharmaceuticals-kresladi-marnetegragene-autotemcel-gene-therapy-for-severe-leukocyte-adhesion-deficiency-i-the-fda-requested-limited-additional-cmc-information
The FDA Issued Complete Response Letter To...
06/28/2024 11:31:33

trading-halt-halted-at-65637-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:56:37 a.m. ET - ...
06/28/2024 10:56:41

european-commission-has-granted-orphan-medicinal-product-designation-for-rocket-pharmaceuticals-rp-a601-an-adeno-associated-virus-aavrh74-based-gene-therapy-candidate-for-plakophilin-2-related-arrhythmogenic-cardiomyopathy
European Commission Has Granted Orphan Med...
05/29/2024 11:16:54

rocket-pharmaceuticals-presents-longer-term-data-updates-from-its-lentiviral-vector-hematology-portfolio-at-asgct
Rocket Pharmaceuticals Presents Longer-Ter...
05/10/2024 10:04:07

Long-term KRESLADI follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplanta...

needham-reiterates-buy-on-rocket-pharmaceuticals-maintains-53-price-target
Needham Reiterates Buy on Rocket Pharmaceu...
05/07/2024 11:17:18

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

rocket-pharmaceuticals-q1-eps-066-beats-069-estimate
Rocket Pharmaceuticals Q1 EPS $(0.66) Beat...
05/06/2024 20:03:12

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate o...

needham-reiterates-buy-on-rocket-pharmaceuticals-maintains-53-price-target
Needham Reiterates Buy on Rocket Pharmaceu...
04/10/2024 10:08:21

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

goldman-sachs-initiates-coverage-on-rocket-pharmaceuticals-with-neutral-rating-announces-price-target-of-39
Goldman Sachs Initiates Coverage On Rocket...
04/02/2024 11:07:21

Goldman Sachs analyst Richard Law initiates coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Neutral rating and annou...

the-european-medicines-agency-accepted-the-marketing-authorization-application-for-rocket-pharmaceuticals-rp-l102-for-fanconi-anemia
The European Medicines Agency Accepted The...
04/02/2024 10:04:04

rocket-pharmaceuticals-announces-appointment-of-aaron-ondrey-as-chief-financial-officer-and-additional-updates-to-corporate-leadership-team
Rocket Pharmaceuticals Announces Appointme...
03/26/2024 20:14:28

Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planni...

ubs-maintains-buy-on-rocket-pharmaceuticals-lowers-price-target-to-54
UBS Maintains Buy on Rocket Pharmaceutical...
03/01/2024 16:53:25

UBS analyst Colin Bristow maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $56 to ...

jp-morgan-maintains-overweight-on-rocket-pharmaceuticals-lowers-price-target-to-50
JP Morgan Maintains Overweight on Rocket P...
02/27/2024 18:25:15

JP Morgan analyst Eric Joseph maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and lowers the price target f...

cantor-fitzgerald-maintains-overweight-on-rocket-pharmaceuticals-maintains-65-price-target
Cantor Fitzgerald Maintains Overweight on ...
02/27/2024 14:31:25

Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and maintains $65 p...

rocket-pharmaceuticals-q4-eps-064-beats-079-estimate
Rocket Pharmaceuticals Q4 EPS $(0.64) Beat...
02/26/2024 21:07:00

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate o...

needham-reiterates-buy-on-rocket-pharmaceuticals-maintains-53-price-target
Needham Reiterates Buy on Rocket Pharmaceu...
02/13/2024 16:46:56

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)